专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012125413A2 COMPOSITIONS FOR AMELIORATING SYSTEMIC INFLAMMATION AND METHODS FOR MAKING AND USING THEM 审中-公开
标题翻译： AMELIORATING系统性炎症的组合物及其制备和使用方法
公开(公告)号：WO2012125413A2
公开(公告)日：2012-09-20
申请号：PCT/US2012/028312
申请日：2012-03-08
申请人： VICUS THERAPEUTICS, LLC , MAKI, John , BASCOMB, Newell , TURNER, Timothy, J.
发明人： MAKI, John , BASCOMB, Newell , TURNER, Timothy, J.
IPC分类号： A61K31/135 , A61K31/535 , A61K31/404 , A61K31/40 , A61K9/20 , A61K9/48 , A61P25/00 , A61P37/00
CPC分类号： A61K31/7072 , A61J1/035 , A61K31/122 , A61K31/135 , A61K31/138 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/192 , A61K31/196 , A61K31/337 , A61K31/365 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/4045 , A61K31/405 , A61K31/407 , A61K31/415 , A61K31/427 , A61K31/454 , A61K31/4745 , A61K31/496 , A61K31/513 , A61K31/52 , A61K31/522 , A61K31/535 , A61K31/536 , A61K31/5377 , A61K31/5415 , A61K31/551 , A61K31/616 , A61K31/662 , A61K31/7056 , A61K38/13 , A61K38/212 , A61K39/39533 , A61K45/06 , A61K2300/00
摘要： In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid- derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.
摘要翻译：在可选实施方式中，本发明提供了组合物，例如药物组合物和制剂，制剂，试剂盒和其他制造产品，例如包装在一起或分开包装在泡罩包装，带盖泡罩或泡罩卡中的示例性药物组合，或包裹在纸，塑料或玻璃纸包装物（例如收缩包装物）中，其包含至少两种活性成分的组合方案，其被设计为通过靶向（抑制）两种不同但收敛的信号传导途径，即交感神经系统和脂质衍生的autacoid系统; 以及制备和使用这些组合物的方法。在可选的实施方案中，本发明的组合物（例如药物组合）用于改善，减少，治疗，阻断或预防继发于感染（例如病毒感染和/或再激活）的炎症反应。 p>

2. 发明申请

WO2016004218A1 COMBINATION DRUG THERAPIES FOR CANCER AND METHODS OF MAKING AND USING THEM 审中-公开
标题翻译：用于癌症的组合药物治疗方法及其使用方法
公开(公告)号：WO2016004218A1
公开(公告)日：2016-01-07
申请号：PCT/US2015/038854
申请日：2015-07-01
申请人： VICUS THERAPEUTICS, LLC
发明人： MAKI, John , BASCOMB, Newell , YOUNG, Fredric
IPC分类号： A61K31/00 , A61P35/00
CPC分类号： A61K31/407 , A61K31/138 , A61K31/155 , A61K31/195 , A61K31/197 , A61K31/341 , A61K31/4045 , A61K31/415 , A61K31/4164 , A61K31/426 , A61K31/47 , A61K31/4706 , A61K31/473 , A61K45/06 , A61K2300/00
摘要： In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices for treating, preventing or ameliorating a tumor or a cancer, and methods for treating, preventing or ameliorating a tumor or a cancer. In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices comprising: a beta adrenergic receptor antagonist (a "beta blocker"); a non-steroidal anti-inflammatory drug (a NSAID); and a therapeutic agent, compound or composition comprising: a H 2 -receptor antagonist (H 2 RA), a melatonin (or an N -acetyl-5-methoxytryptamine), a metformin, a quinoline (e.g., chloroquine), an immune checkpoint blockade agent, or an agent that blocks the interaction between a transmembrane programmed cell death 1 protein, or any combination thereof. In alternative embodiments, the therapeutic combinations of therapeutic agents or drugs further comprise an anti-cancer or anti-tumor antibody, a cytokine, and/or a chemotherapeutic agent.
摘要翻译：在替代实施方案中，提供了用于治疗，预防或改善肿瘤或癌症的治疗组合，药物组合物，制剂，试剂盒和装置，以及用于治疗，预防或改善肿瘤或癌症的方法。在替代实施方案中，提供了治疗组合，药物组合物，制剂，试剂盒和装置，其包含：β肾上腺素能受体拮抗剂（“β阻滞剂”）; 非甾体抗炎药（NSAID）; 以及治疗剂，化合物或组合物，其包含：H 2受体拮抗剂（H2RA），褪黑激素（或N-乙酰基-5-甲氧基色胺），二甲双胍，喹啉（例如氯喹），免疫检查点封闭剂，或阻断跨膜程序性细胞死亡1蛋白或其任何组合之间的相互作用的试剂。在替代实施方案中，治疗剂或药物的治疗组合进一步包含抗癌或抗肿瘤抗体，细胞因子和/或化学治疗剂。

3. 发明申请

WO2016004213A2 HYDROGELS FOR TREATING AND AMELIORATING CANCERS AND POTENTIATING THE IMMUNE SYSTEM AND METHODS OF MAKING AND USING THEM 审中-公开
标题翻译：用于治疗和减轻癌症并强化免疫系统的水凝胶及其制备和使用方法
公开(公告)号：WO2016004213A2
公开(公告)日：2016-01-07
申请号：PCT/US2015/038849
申请日：2015-07-01
申请人： VICUS THERAPEUTICS, LLC
发明人： MAKI, John , BASCOMB, Newell , YOUNG, Fredric
IPC分类号： A61K47/34 , A61K47/32
CPC分类号： A61K47/42 , A61K9/0019 , A61K9/0024 , A61K31/138 , A61K31/407 , A61K38/2013 , A61K45/06 , A61K2300/00
摘要： In alternative embodiments, provided are pharmaceutical compositions, formulations, kits and other products of manufacture, comprising a sterile hydrogel comprising a hydrogel material and active ingredients including one or a plurality of compositions or compounds, which may comprise: a biologic, a drug or an immunostimulating agent or reagent; an antigen or an immunogen, or a plurality of antigens or immunogens; an anticancer agent or reagent, or any combination thereof.
摘要翻译：在可选实施方式中，提供了药物组合物，制剂，试剂盒和其他制造产品，其包含包含水凝胶材料的无菌水凝胶和包含一种或多种组合物或化合物的活性成分，所述组合物或化合物可包含：生物制剂，药物或免疫刺激剂或试剂; 抗原或免疫原或多种抗原或免疫原; 抗癌剂或试剂，或其任何组合。

4. 发明申请

WO2009111648A1 COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES 审中-公开
标题翻译：组织学和肿瘤学治疗方法
公开(公告)号：WO2009111648A1
公开(公告)日：2009-09-11
申请号：PCT/US2009/036205
申请日：2009-03-05
申请人： VICUS THERAPEUTICS, LLC , BASCOMB, Newell , MAKI, John , YOUNG, Fredric, S.
发明人： BASCOMB, Newell , MAKI, John , YOUNG, Fredric, S.
IPC分类号： A61P35/00 , A61K31/195 , A61K45/06 , A61K31/00 , A61K31/407
CPC分类号： A61K39/39558 , A23L33/10 , A23V2002/00 , A61J1/035 , A61J1/10 , A61J3/02 , A61J3/06 , A61J3/07 , A61J3/08 , A61J3/10 , A61J7/0084 , A61K9/0053 , A61K9/127 , A61K31/10 , A61K31/12 , A61K31/138 , A61K31/192 , A61K31/196 , A61K31/197 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/415 , A61K31/42 , A61K31/4412 , A61K31/444 , A61K31/506 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K31/593 , A61K31/7072 , A61K39/3955 , A61K45/06 , A61K2039/505 , B65D71/0085 , B65D75/002 , B65D75/36 , B65D75/366 , B65D75/368 , A61K2300/00
摘要： In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies.
摘要翻译：在替代实施方案中，本发明提供用于治疗癌症或由功能障碍性细胞引起的任何病症的组合物和方法，治疗癌症或由功能障碍性细胞引起的任何病症的副作用，例如粘膜炎治疗（例如，用于口腔粘膜炎;消化性粘膜炎;食管粘膜炎;肠粘膜炎）。在替代实施方案中，本发明提供了可以单独使用或与其他医学疗法如癌症化学疗法和放射治疗组合使用的细胞保护产物。

5. 发明申请

WO2019090141A1 COMBINATION DRUG THERAPIES FOR CANCER AND METHODS OF MAKING AND USING THEM 审中-公开
公开(公告)号：WO2019090141A1
公开(公告)日：2019-05-09
申请号：PCT/US2018/059047
申请日：2018-11-02
申请人： VICUS THERAPEUTICS, LLC
发明人： MAKI, John , BASCOMB, Newell , YOUNG, Fredric
IPC分类号： A61K31/138 , A61K31/407 , B65D75/36
CPC分类号： A61K31/138 , A61K9/1676 , A61K9/5078 , A61K9/5084 , A61K31/407 , A61K2300/00
摘要： In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices for treating, preventing or ameliorating a tumor or a cancer, and methods for treating, preventing or ameliorating a tumor or a cancer. In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices comprising: a beta adrenergic receptor antagonist (a "beta blocker", such as propranolol); a non-steroidal anti-inflammatory drug (a NSAID, such as etodolac) packaged or formulated for chronodosed and pulsatile release such that they can be administered two times a day (BID), and methods for making and using them, e.g., in treatment regimens. In alternative embodiments, the therapeutic combinations of therapeutic agents or drugs further comprise an anti-cancer or anti-tumor antibody, a cytokine, and/or another chemotherapeutic agent.

6. 发明申请

WO2017120092A1 COMBINATION COMPOSITIONS 审中-公开
标题翻译：组合组合物
公开(公告)号：WO2017120092A1
公开(公告)日：2017-07-13
申请号：PCT/US2016/069133
申请日：2016-12-29
申请人： 3-D MATRIX, LTD. , VICUS THERAPEUTICS, LLC
发明人： MAKI, John , GIL, Eun Seok , SPIRIO, Lisa
IPC分类号： A61K38/08 , A61L27/22 , A61K38/10
CPC分类号： A61K38/08 , A61K9/0019 , A61K38/10 , A61K47/42 , A61L27/227
摘要： Combination compositions comprising self-assembling peptides and payload agents, and methods of making and using such compositions, are described.
摘要翻译：描述了包含自组装肽和有效载荷剂的组合组合物，以及制备和使用该组合物的方法。

7. 发明申请

WO2016061135A1 DRUG COMBINATIONS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND METHODS OF MAKING AND USING THEM 审中-公开
标题翻译：与选择性受体调节剂（SARMS）的药物组合及其制备和使用方法
公开(公告)号：WO2016061135A1
公开(公告)日：2016-04-21
申请号：PCT/US2015/055383
申请日：2015-10-13
申请人： VICUS THERAPEUTICS, LLC
发明人： MAKI, John , BASCOMB, Newell , YOUNG, Fredric
IPC分类号： A61K31/402
CPC分类号： A61K31/402 , A61K45/06 , A61K2300/00
摘要： In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices comprising drug combinations including a selective androgen receptor modulator (SARM), e.g., such as enobosarm or andarine, with one or more additional drugs or active agents, and methods for making and using them for treating, ameliorating, reversing or preventing a cancer such as a breast cancer, a basal-like carcinoma, a ductal carcinoma or an ovarian cancer, a tumor, a burn or a short stature or related syndrome or condition.
摘要翻译：在替代实施方案中，提供了治疗组合，药物组合物，制剂，试剂盒和包含药物组合的装置，包括选择性雄激素受体调节剂（SARM），例如enobosarm或orarine与一种或多种另外的药物或活性剂，以及方法用于制造和使用它们用于治疗，改善，逆转或预防癌症如乳腺癌，基底样癌，导管癌或卵巢癌，肿瘤，烧伤或身材矮小或相关综合征或病症。

8. 发明申请

WO2016004216A2 HYDROGELS FOR TREATING AND AMELIORATING INFECTIONS AND METHODS OF MAKING AND USING THEM 审中-公开
标题翻译：用于治疗和改善感染的水凝胶及其制备和使用方法
公开(公告)号：WO2016004216A2
公开(公告)日：2016-01-07
申请号：PCT/US2015/038852
申请日：2015-07-01
申请人： VICUS THERAPEUTICS, LLC
发明人： MAKI, John , BASCOMB, Newell , YOUNG, Fredric , GILL, Eun, Seok
IPC分类号： A61K47/34 , A61K47/32
CPC分类号： A61K47/32 , A61K9/0024 , A61K47/34
摘要： In alternative embodiments, the invention provides pharmaceutical compositions, formulations, kits and other products of manufacture, and methods, for treating, ameliorating (e.g., reducing the severity of, slowing the progress of) or preventing infections, comprising local administration of drugs via a hydrogel component or material, wherein optionally amount or concentration of drugs in the hydrogel component or material is a "very high" or an "ultra-high" dose of drugs. In alternative embodiments, the products of manufacture, devices, kits, and compositions, and methods as provided herein are antimicrobial and target infections caused, e.g., by multiple drug resistance organisms (MDROs), or a methicillin-resistant Staphylococcus aureus (MRSAs), or a biofilm. In alternative embodiments, skin, skin structure or bone infections are treated, ameliorated or prevented by products of manufacture, devices, kits, and compositions, and methods as provided herein.
摘要翻译：在替代实施方案中，本发明提供药物组合物，制剂，试剂盒和其它制造产品，以及用于治疗，改善（例如降低其进展的严重性，减缓进展）或预防感染的制造方法，包括经由水凝胶组分或材料，其中在水凝胶组分或材料中任选量或浓度的药物是“非常高”或“超高”剂量的药物。在替代实施方案中，本文提供的制品，装置，试剂盒，组合物和方法的产品是例如由多种耐药性生物体（MDRO）或耐甲氧西林金黄色葡萄球菌（MRSA）引起的抗微生物剂和靶感染，或生物膜。在替代实施方案中，皮肤，皮肤结构或骨感染由本文提供的制造产品，装置，试剂盒和组合物以及方法进行治疗，改善或预防。

9. 发明申请

WO2016004212A1 HYDROGELS FOR TREATING AND AMELIORATING WOUNDS AND METHODS FOR MAKING AND USING THEM 审中-公开
标题翻译：用于治疗和改善创伤的水晶及其制备和使用它们的方法
公开(公告)号：WO2016004212A1
公开(公告)日：2016-01-07
申请号：PCT/US2015/038848
申请日：2015-07-01
申请人： VICUS THERAPEUTICS, LLC
发明人： MAKI, John , BASCOMB, Newell , YOUNG, Fredric
IPC分类号： A61K35/12 , A61K35/36 , A61P17/02
CPC分类号： A61L27/60 , A61F2/105 , A61K31/07 , A61K31/16 , A61K31/195 , A61K31/197 , A61K31/355 , A61K31/375 , A61K31/455 , A61K31/56 , A61K31/7036 , A61K35/28 , A61K35/36 , A61K38/1816 , A61K38/1825 , A61K38/193 , A61L27/362 , A61L27/3641 , A61L27/3687 , A61L27/3691 , A61L27/52 , A61L27/54 , A61L27/56 , A61L2300/25 , A61L2300/406 , A61L2300/414 , A61L2300/418 , A61L2300/45 , A61L2430/34 , A61K2300/00
摘要： In alternative embodiments, provided are compositions, e.g., pharmaceutical compositions, formulations, kits and other products of manufacture, comprising a hydrogel and active ingredients, including mixed thickness skin micrografts, or full or split-thickness skin grafts, contained or mixed in or within the hydrogel; and methods for making and using them. In alternative embodiments, compositions and methods as provided herein are used for the treatment or amelioration of wounds and surgical sites, and include compositions and methods for micrografting, or for micrografting a wound, or for micrografting a wound for rapid re-epithelialization, or for micrografting a wound for rapid re-epithelialization of large non-healing wounds.
摘要翻译：在替代实施方案中，提供了组合物，例如药物组合物，制剂，试剂盒和其他制造产品，其包含水凝胶和活性成分，包括混合的厚度皮肤微移植物，或全部或分裂的皮肤移植物，其包含或混合在其中或内部水凝胶以及制作和使用它们的方法。在替代实施例中，本文提供的组合物和方法用于治疗或改善伤口和外科手术部位，并且包括用于微移植，或用于微创伤的组合物和方法，或用于微创伤以快速重新上皮化，或用于微创伤口用于快速重新上皮化大的非愈合伤口。

10. 发明申请

WO2012099962A3 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MAKING AND USING THEM 审中-公开
公开(公告)号：WO2012099962A3
公开(公告)日：2012-07-26
申请号：PCT/US2012/021724
申请日：2012-01-18
申请人： VICUS THERAPEUTICS, LLC , MAKI, John , BASCOMB, Newell , TURNER, Timothy, J.
发明人： MAKI, John , BASCOMB, Newell , TURNER, Timothy, J.
IPC分类号： A61K31/455 , A61K31/20 , A61K31/133 , A61K9/06 , A61K9/70 , A61K9/12
摘要： In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising combinations of beneficial ingredients that in alternative embodiments are serviceable as therapies or palliatives for treating, preventing or improving conditions, states and disease symptoms involving the use of targeted protein kinase inhibitors such as Multi-Kinase Inhibitors (MKIs) or Epidermal Growth Factor Receptor (EGFR) Inhibitors (EGFRIs), or the use of other oral oncolytics, such as capcitabine or erlotinib, known to be associated with drug-induced dermatological toxicity, e.g., in the amelioration or treatment of a cancer, a dermatitis, a rosacea, an eczema, an ichthyosis, or a related condition; and methods for making and using these compositions; and methods for making and using these compositions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式